跳转至内容
Merck
CN

I0786

IGF1R (960-end), active, His tagged human

PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

别名:

CD221, JTK13, MGC142170, MGC142172

登录 查看组织和合同定价。

选择尺寸

关于此项目

NACRES:
NA.32
UNSPSC Code:
51111800
Specific activity:
224-302 nmol/min·mg
Assay:
≥70% (SDS-PAGE)
Recombinant:
expressed in baculovirus infected Sf9 cells

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

recombinant

expressed in baculovirus infected Sf9 cells

product line

PRECISIO® Kinase

assay

≥70% (SDS-PAGE)

form

buffered aqueous glycerol solution

specific activity

224-302 nmol/min·mg

mol wt

~53 kDa

UniProt accession no.

P08069

relevant disease(s)

cancer

shipped in

dry ice

storage temp.

−70°C

Quality Level

200

Gene Information

human ... IGF1R(3480)

Biochem/physiol Actions

IGF1R (insulin-like growth factor 1 receptor) is a transmembrane tyrosine kinase receptor that is activated by IGF1 (insulin-like growth factor 1) as well as IGF2. IGF1R plays a key role in tumorigenesis. The IGF1R is implicated in several cancers, most notably breast cancer where it is highly overexpressed and causes disease progression and poor prognosis. In many instances, IGF1R overexpression allows cancerous cells to resist the cytotoxic properties of chemotheraputic drugs or radiotherapy.

Physical form

Supplied in 50 mM Sodium Phosphate, pH 7.0, with 150 mM imidazole, 0.1 mM PMSF, 0.2 mM DTT, and 25% glycerol.

Legal Information

PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Tracking changes in hypothalamic IGF-1 sensitivity with aging and caloric restriction.
Yaghmaie, F., et al.
Experimental Gerontology, 42, 148-149 (2007)
H E Jones et al.
Endocrine-related cancer, 11(4), 793-814 (2004-12-23)
De novo and acquired resistance to the anti-tumour drug gefitinib (ZD1839; Iressa), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been reported. We have determined whether signalling through the IGF-I receptor (IGF-1R) pathway plays a role

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持